Abstract
A PtIV prodrug needs to be reduced to PtII by a biomolecule in order to show efficacy. Among biomolecules, those containing an l-Cys residue have the highest potential to be involved in reduction. Tautomerisation from HSCH2CH(NH3+)CO2− to the unusual zwitterion form −SCH2CH(NH3+)CO2H is the prerequisite for l-Cys to become a potent reductant at a low pH.
Original language | English |
---|---|
Pages (from-to) | 10491-10494 |
Number of pages | 4 |
Journal | Chemical Communications |
Volume | 54 |
Issue number | 74 |
DOIs | |
Publication status | Published - 2018 |
Externally published | Yes |